Citations to this article
Roya M. Dayam, … , Anne-Claude Gingras, Tania H. Watts
Published April 26, 2022
Citation Information: JCI Insight. 2022;7(11):e159721. https://doi.org/10.1172/jci.insight.159721.
Citation Information: JCI Insight. 2022;7(11):e159721. https://doi.org/10.1172/jci.insight.159721.
Abstract
BACKGROUND Limited information is available on the impact of immunosuppressants on COVID-19 vaccination in patients with immune-mediated inflammatory diseases (IMID).METHODS This observational cohort study examined the immunogenicity of SARS-CoV-2 mRNA vaccines in adult patients with inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, or psoriatic disease, with or without maintenance immunosuppressive therapies. Ab and T cell responses to SARS-CoV-2, including neutralization against SARS-CoV-2 variants, were determined before and after 1 and 2 vaccine doses.RESULTS We prospectively followed 150 subjects, 26 healthy controls, 9 patients with IMID on no treatment, 44 on anti-TNF, 16 on anti-TNF with methotrexate/azathioprine (MTX/AZA), 10 on anti–IL-23, 28 on anti–IL-12/23, 9 on anti–IL-17, and 8 on MTX/AZA. Ab and T cell responses to SARS-CoV-2 were detected in all participants, increasing from dose 1 to dose 2 and declining 3 months later, with greater attrition in patients with IMID compared with healthy controls. Ab levels and neutralization efficacy against variants of concern were substantially lower in anti-TNF–treated patients than in healthy controls and were undetectable against Omicron by 3 months after dose 2.CONCLUSIONS Our findings support the need for a third dose of the mRNA vaccine and for continued monitoring of immunity in these patient groups.FUNDING Funded by a donation from Juan and Stefania Speck and by Canadian Institutes of Health (CIHR)/COVID-Immunity Task Force (CITF) grants VR-1 172711 and VS1-175545 (to THW and ACG), CIHR FDN-143250 (to THW), GA2-177716 (to VC, ACG, and THW), and GA1-177703 (to ACG) and the CIHR rapid response network to SARS-CoV-2 variants, CoVaRR-Net (to ACG).
Authors
Roya M. Dayam, Jaclyn C. Law, Rogier L. Goetgebuer, Gary Y.C. Chao, Kento T. Abe, Mitchell Sutton, Naomi Finkelstein, Joanne M. Stempak, Daniel Pereira, David Croitoru, Lily Acheampong, Saima Rizwan, Klaudia Rymaszewski, Raquel Milgrom, Darshini Ganatra, Nathalia V. Batista, Melanie Girard, Irene Lau, Ryan Law, Michelle W. Cheung, Bhavisha Rathod, Julia Kitaygorodsky, Reuben Samson, Queenie Hu, W. Rod Hardy, Nigil Haroon, Robert D. Inman, Vincent Piguet, Vinod Chandran, Mark S. Silverberg, Anne-Claude Gingras, Tania H. Watts
Citation information
Citations to this article (38)
| Title and authors | Publication | Year |
|---|---|---|
|
Neutralizing Antibody Response to SARS-CoV-2 Variants After Two mRNA COVID-19 Vaccine Doses in a Cohort of Patients with Inflammatory Bowel Disease from a Southern Italy Tertiary Hospital
Genovese D, Brinch D, Muscarella S, Saladino M, Carrozza L, Cunsolo C, Sanfilippo GL, Amodio E, Cappello M, Ferraro D |
Healthcare | 2025 |
|
mRNA vaccine-induced SARS-CoV-2 spike-specific IFN-γ and IL-2 T-cell responses are predictive of serological neutralization and are transiently enhanced by pre-existing cross-reactive immunity
Samaan P, Korosec CS, Budylowski P, Chau SL, Pasculescu A, Qi F, Delgado-Brand M, Tursun TR, Mailhot G, Dayam RM, Arnold CR, Langlois MA, Mendoza J, Morningstar T, Law R, Mihelic E, Sheikh-Mohamed S, Cao EY, Paul N, Patel A, de Launay KQ, Boyd JM, Takaoka A, Colwill K, Matveev V, Yue FY, McGeer A, Straus S, Gingras AC, Heffernen JM, Ostrowski M |
Journal of Virology | 2025 |
|
Evaluation of SARS-CoV-2 Vaccine-Induced Antibody Responses in Patients with Neuroimmunological Disorders: A Real-World Experience
Ju H, Seok JM, Chung YH, Jeon MY, Lee HL, Kwon S, Kim S, Min JH, Kim BJ |
Diagnostics | 2024 |
|
SARS-CoV-2 booster vaccine dose significantly extends humoral immune response half-life beyond the primary series.
Korosec CS, Dick DW, Moyles IR, Watmough J |
Scientific Reports | 2024 |
|
The serological immunogenicity of the third and fourth doses of COVID-19 vaccine in patients with inflammatory rheumatic diseases on different biologic or targeted DMARDs: a Swedish nationwide study (COVID-19-REUMA).
Frodlund M, Nived P, Chatzidionysiou K, Södergren A, Klingberg E, Hansson M, Ohlsson S, Pin E, Bengtsson A, Klareskog L, Kapetanovic M |
Microbiology spectrum | 2024 |
|
4th booster-dose SARS-CoV-2 heterologous and homologous vaccination in rheumatological patients
Gallardo-Nelson MJ, Cruces M, Gómez YM, Fuenzalida C, Silva J, Aravena-Traipi L, Nuñez E, Gaete-Angel A, Rivas-Yañez E, Kalergis AM, Soto-Rifo R, Valiente-Echeverria F |
Frontiers in immunology | 2024 |
|
Methotrexate and Tumor Necrosis Factor Inhibitors Independently Decrease Neutralizing Antibodies after SARS-CoV-2 Vaccination: Updated Results from the SUCCEED Study
Hitchon CA, Bowdish DM, Boire G, Fortin PR, Flamand L, Chandran V, Dayam RM, Gingras AC, Card CM, Colmegna I, Larché MJ, Kaplan GG, Lukusa L, Lee JL, Bernatsky S |
Vaccines | 2024 |
|
Kinetics of humoral and cellular immune responses 5 months post-COVID-19 booster dose by immune response groups at the peak immunity phase: An observational historical cohort study using the Fukushima vaccination community survey
Kobashi Y, Kawamura T, Shimazu Y, Kaneko Y, Nishikawa Y, Sugiyama A, Tani Y, Nakayama A, Yoshida M, Zho T, Yamamoto C, Saito H, Takita M, Wakui M, Kodama T, Tsubokura M |
Vaccine: X | 2024 |
|
Did We Overreact? Insights on COVID-19 Disease and Vaccination in a Large Cohort of Immune-Mediated Inflammatory Disease Patients during Sequential Phases of the Pandemic (The BELCOMID Study).
Geldof J, Truyens M, Sabino J, Ferrante M, Lambert J, Lapeere H, Hillary T, Van Laethem A, de Vlam K, Verschueren P, Lobaton T, Padalko E, Vermeire S |
Vaccines | 2024 |
|
Duration of Postvaccination Neutralizing Antibodies to SARS-CoV-2 and Medication Effects: Results from the Safety and Immunogenicity of COVID-19 Vaccination in Systemic Immune-Mediated Inflammatory Diseases Cohort Study.
Habib R, Dayam RM, Hitchon C, Chandran V, Fortin PR, Boire G, Bowdish DME, Gingras AC, Flamand L, Larché MJ, Colmegna I, Lukusa L, Lee JLF, Pereira D, Bernstein CN, Lalonde N, Turnbull E, Bernatsky S |
ACR open rheumatology | 2024 |
|
Impacts of delta and omicron variants on inactivated SARS-CoV-2 vaccine-induced T cell responses in patients with autoimmune diseases and healthy controls.
Wang S, Li J, Wang S, Ye Y, Li M, Liu Y, Chen B, Lai Y, Li L, Zhuang L, Peng S, Yang N, Zhang H, Xiao H |
Clinical and Translational Medicine | 2023 |
|
Assessment of the longitudinal humoral response in non-hospitalized SARS-CoV-2-positive individuals at decentralized sites: Outcomes and concordance
Djaïleb A, Lavallée É, Parker MF, Cayer MP, Desautels F, de Grandmont MJ, Stuible M, Gervais C, Durocher Y, Trottier S, Boudreau D, Masson JF, Brouard D, Pelletier JN |
Frontiers in immunology | 2023 |
|
The accelerated waning of immunity and reduced effect of booster in patients treated with bDMARD and tsDMARD after SARS-CoV-2 mRNA vaccination
Tobudic S, Simader E, Deimel T, Straub J, Kartnig F, Heinz LX, Mandl P, Haslacher H, Perkmann T, Schneider L, Nothnagl T, Radner H, Winkler F, Burgmann H, Stiasny K, Novacek G, Reinisch W, Aletaha D, Winkler S, Blüml S |
Frontiers in Medicine | 2023 |
|
Third and fourth vaccine doses broaden and prolong immunity to SARS-CoV-2 in immunocompromised adult patients
Michelle Cheung, Roya Dayam, Janna Shapiro, Jaclyn Law, Gary Chao, Daniel Pereira, Rogier Goetgebuer, David Croitoru, Joanne Stempak, Lily Acheampong, Saima Rizwan, Jenny D Lee, Liz Jacob, Darshini Ganatra, Ryan Law, Victoria E Rodriguez-Castellanos, Madeline Kern-Smith, Melanie Delgado-Brand, Genevieve Mailhot, Nigil Haroon, Robert Inman, Vincent Piguet, Vinod Chandran, Mark Silverberg, Tania Watts, Anne-Claude Gingras. |
Journal of immunology (Baltimore, Md. : 1950) | 2023 |
|
T Cells Remember SARS-CoV-2 in Rituximab-Treated Pemphigus Vulgaris
Croitoru DO, Piguet V |
Journal of Investigative Dermatology | 2023 |
|
The Third Dose of BNT162b2 COVID-19 Vaccine Does Not “Boost” Disease Flares and Adverse Events in Patients with Rheumatoid Arthritis
Picchianti Diamanti A, Navarra A, Cuzzi G, Aiello A, Salemi S, Di Rosa R, De Lorenzo C, Vio D, Sebastiani G, Ferraioli M, Benucci M, Li Gobbi F, Cantini F, Polidori V, Simmaco M, Cialdi E, Scolieri P, Bruzzese V, Nicastri E, D\u2019Amelio R, Laganà B, Goletti D |
Biomedicines | 2023 |
|
The impact of immunomodulating treatment on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases compared to healthy controls. A Swedish nationwide study (COVID19-REUMA)
Frodlund M, Nived P, Chatzidionysiou A, Södergren A, Klingberg E, Bengtsson A, Hansson M, Olsson S, Pin E, Klareskog L, Kapetanovic MC |
Vaccine | 2023 |
|
Comparison of COVID-19 Vaccination and Infection Rates in Adult Patients With Autoimmune Inflammatory Disease on b/tsDMARD Therapy
Avlasevich V, McCarthy K |
The Annals of pharmacotherapy | 2023 |
|
HLA Variation and SARS-CoV-2 Specific Antibody Response
Wolday D, Fung CY, Morgan G, Casalino S, Frangione E, Taher J, Lerner-Ellis JP |
Viruses | 2023 |
|
Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies
Wolff AS, Hansen L, Grytaas MA, Oftedal BE, Breivik L, Zhou F, Hufthammer KO, Sjøgren T, Olofsson JS, Trieu MC, Meager A, Jørgensen AP, Lima K, Greve-Isdahl Mohn K, Langeland N, Cox RJ, Husebye ES |
iScience | 2023 |
|
Effect of DMARDs on the immunogenicity of vaccines.
van Sleen Y, van der Geest KSM, Huckriede ALW, van Baarle D, Brouwer E |
Nature reviews. Rheumatology | 2023 |
|
The Intersection of COVID-19 and Rheumatoid Arthritis: Shared Mechanisms, Treatment Challenges, and Potential Therapeutic Approaches.
Xiao J, Liang C, Zhang L, Li J, Liu S |
Aging and disease | 2023 |
|
Hydroxychloroquine reduces T cells activation recall antigen responses.
Kowatsch MM, Lajoie J, Mwangi L, Omollo K, Oyugi J, Hollett N, Kimani J, Fowke KR |
PloS one | 2023 |
|
SARS-CoV-2 mRNA vaccine-induced immune responses in rheumatoid arthritis
Limoges MA, Lortie A, Demontier É, Quenum AJ, Lessard F, Drouin Z, Carrier N, Nguimbus LM, Beaulieu MC, Boire G, Piché A, Allard-Chamard H, Ramanathan S, Roux S |
Journal of leukocyte biology | 2023 |
|
Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases: A Systematic Review and Meta-Analysis
Widhani A, Hasibuan AS, Rismawati R, Maria S, Koesnoe S, Hermanadi MI, Ophinni Y, Yamada C, Harimurti K, Sari AN, Yunihastuti E, Djauzi S |
Human vaccines | 2023 |
|
Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine.
Picchianti-Diamanti A, Navarra A, Aiello A, Laganà B, Cuzzi G, Salmi A, Vanini V, Maggi F, Meschi S, Matusali G, Notari S, Agrati C, Salemi S, Di Rosa R, Passarini D, Di Gioia V, Sesti G, Conti F, Spinelli FR, Corpolongo A, Chimenti MS, Ferraioli M, Sebastiani GD, Benucci M, Li Gobbi F, Santoro AP, Capri A, Puro V, Nicastri E, Goletti D |
Human vaccines | 2023 |
|
Immunomodulatory drugs have divergent effects on humoral and cellular immune responses to SARS-CoV-2 vaccination in people living with rheumatoid arthritis.
Benoit JM, Breznik JA, Ang JC, Bhakta H, Huynh A, Cowbrough B, Baker B, Heessels L, Lodhi S, Yan E, Ewusie J, Nazy I, Bramson J, Miller MS, Bernatsky S, Larché MJ, Bowdish DME |
Scientific Reports | 2023 |
|
Rheumatoid arthritis and older age are associated with lower humoral and cellular immune response to primary series COVID-19 mRNA vaccine
Dudley HM, O\u2019Mara M, Auma A, Gong J, Ross Y, Gurevich N, Carbone S, Reihs A, Nguyen Y, McComsey GA, Cao Y, Balazs AB, Gordesky L, Payne M, Singer N, Kostadinova L, Wilson B, Zidar DA, King CL, Canaday DH, Shive CL, Mattar MM, Anthony DD |
Vaccine | 2023 |
|
A Qualitative Comparison of the Abbott SARS-CoV-2 IgG II Quant Assay against Commonly Used Canadian SARS-CoV-2 Enzyme Immunoassays in Blood Donor Retention Specimens, April 2020 to March 2021.
Abe KT, Rathod B, Colwill K, Gingras AC, Tuite A, Robbins NF, Orjuela G, Jenkins C, Conrod V, Yi QL, O'Brien SF, Drews SJ |
Microbiology spectrum | 2022 |
|
Third dose corrects waning immunity to SARS-CoV-2 mRNA vaccines in immunocompromised patients with immune-mediated inflammatory diseases
Cheung MW, Dayam RM, Law JC, Goetgebuer RL, Chao GY, Finkelstein N, Stempak JM, Pereira D, Croitoru D, Acheampong L, Rizwan S, Lee JD, Ganatra D, Law R, Delgado-Brand M, Mailhot G, Piguet V, Silverberg MS, Watts TH, Gingras AC, Chandran V |
RMD Open | 2022 |
|
Clinical outcomes and immune responses to SARS‐CoV‐2 vaccination in severe aplastic anaemia
Rajput RV, Ma X, Boswell KL, Gaudinski M, Gordon I, Novik L, Groarke EM, Lotter J, Superata J, Rios OJ, Darden I, Lin BC, Jean\u2010Baptiste N, Carroll R, Moore C, Trost J, Naisan M, Willis J, Serebryannyy L, Wang JL, Prabhakaran M, Narpala SR, Koup RA, McDermott A, Wu CO, Young NS, Patel BA |
British Journal of Haematology | 2022 |
|
Utilization of the Abbott SARS-CoV-2 IgG II Quant Assay To Identify High-Titer Anti-SARS-CoV-2 Neutralizing Plasma against Wild-Type and Variant SARS-CoV-2 Viruses.
Lin YJ, Evans DH, Robbins NF, Orjuela G, Hu Q, Samson R, Abe KT, Rathod B, Colwill K, Gingras AC, Tuite A, Yi QL, O'Brien SF, Drews SJ |
Microbiology spectrum | 2022 |
|
Factors influencing the SARS-CoV-2 infection and vaccination induced immune response in rheumatoid arthritis
Nemeth D, Vago H, Tothfalusi L, Ulakcsai Z, Becker D, Szabo Z, Rojkovich B, Merkely B, Nagy G |
Frontiers in immunology | 2022 |
|
Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study.
Farroni C, Aiello A, Picchianti-Diamanti A, Laganà B, Petruccioli E, Agrati C, Garbuglia AR, Meschi S, Lapa D, Cuzzi G, Petrone L, Vanini V, Salmi A, Altera AMG, Repele F, Grassi G, Bettini A, Vita S, Mariano A, Damiani A, Infantino M, Grossi V, Manfredi M, Niccoli L, Puro V, Rosa RD, Salemi S, Sesti G, Scolieri P, Bruzzese V, Benucci M, Cantini F, Nicastri E, Goletti D |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 2022 |
|
SARS-CoV-2 infection among patients with autoimmune rheumatic diseases; comparison between the Delta and Omicron waves in Israel
Bieber A, Brikman S, Novack L, Ayalon S, Abu-Shakra M, Zeller L, Mader R, Sagy I |
Seminars in Arthritis and Rheumatism | 2022 |
|
Humoral Responses in the Omicron Era Following 3-Dose SARS-CoV-2 Vaccine Series in Kidney Transplant Recipients
McEvoy CM, Hu Q, Abe KT, Yau K, Oliver MJ, Levin A, Gingras AC, Hladunewich MA, Yuen DA |
Transplantation Direct | 2022 |
|
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study
Liu Z, Le K, Zhou X, Alexander JL, Lin S, Bewshea C, Chanchlani N, Nice R, McDonald TJ, Lamb CA, Sebastian S, Kok K, Lees CW, Hart AL, Pollok RC, Boyton RJ, Altmann DM, Pollock KM, Goodhand JR, Kennedy NA, Ahmad T, Powell N |
The Lancet Gastroenterology & Hepatology | 2022 |
|
Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies
Aiello A, Coppola A, Ruggieri S, Farroni C, Altera AM, Salmi A, Vanini V, Cuzzi G, Petrone L, Meschi S, Lapa D, Bettini A, Haggiag S, Prosperini L, Galgani S, Quartuccio ME, Bevilacqua N, Garbuglia AR, Agrati C, Puro V, Tortorella C, Gasperini C, Nicastri E, Goletti D |
Journal of neurology, neurosurgery, and psychiatry | 2022 |
